Prospective Observational Study Of Patients With Polycythemia Vera In US Clinical Practices (REVEAL)

Inclusion Criteria:

Age ≥18 years
Diagnosis of Polycythemia Vera (PV)
Willing and able to provide written informed consent
Willing and able to complete patient assessment questionnaires either alone or with minimal assistance from a caregiver and/or trained site personnel
Under the supervision of a physician for the current care of PV including but not limited to watchful waiting, acetylsalicylic acid (ASA) 81mg or greater, antithrombotic therapy, Phlebotomy (PHL), Hydroxyurea (HU), interferon (recombinant or pegylated), busulfan, anagrelide

Exclusion Criteria:

Participation in an active clinical trial in which the study treatment is blinded
Life expectancy <6 months
Diagnosis of myelofibrosis (MF) [including primary MF, post-PV MF, or post-essential thrombocythemia MF (post-ET MF)]
Diagnosis of secondary Acute Myeloid Leukemia (AML)
Diagnosis of Myelodysplastic Syndrome (MDS)
History of or active plan to proceed to allogeneic hematopoietic stem cell transplant in next 3 months
Splenectomy